Skye Bioscience (SKYE) Proxy filing summary

Executive summary

• Announced resignation of Chief Financial Officer John P. Sharp, effective September 8, 2026, and appointment of CEO Punit Dhillon as principal financial and accounting officer.

• Terminated the Master Services Agreement with Lohman & Associates, Inc. effective September 8, 2026, in connection with the CFO's resignation.

• Regained compliance with Nasdaq's minimum bid price requirement after maintaining a closing bid price of at least $1.00 for 10 consecutive business days.

• Provided forward-looking statements regarding the anticipated acquisition of Redx Pharma Limited and related risks.

Voting matters and shareholder proposals

• Plans to file a proxy statement with the SEC for a special meeting of stockholders to approve the proposed acquisition of Redx Pharma Limited.

• Urges stockholders to read the proxy statement and related documents for important information about the transaction.

Board of directors and corporate governance

• CEO Punit Dhillon appointed as principal financial and accounting officer, with no changes to his compensatory or other material terms.

• No family relationships or material interests between Mr. Dhillon and other directors or executive officers.